Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
No pink
Improving Adherence and Accessibility of GLP-1 Therapies in Adolescents Despite their benefits, adherence challenges remain a major concern, particularly among adolescents who may struggle with long-term commitment to injectable medications
Food and Drug Administration (FDA) approved the first GLP-1 agonist, indicated for the treatment of type 2 diabetes
Clinical trials have demonstrated substantial reductions in hemoglobin A1c levels (up to 2.0% or more) in type 2 diabetes, and in the SURMOUNT trials, significant weight loss (up to approximately 21% at the 15 mg dose) in patients with obesity
US$ 26.97
US$ 26.31
US$ 25.69
US$ 20.13
US$ 24.59
US$ 29.45
US$ 22.15
